Fusion protein complexes for epigenetic regulation, cancer treatment

USPTO published patent application US20260092267A1 for fusion protein complexes comprising a transcription enhancer linked to dCas9 protein, combined with guide RNAs (gRNAs) for epigenetic regulation. The application covers pharmaceutical compositions for inducing apoptosis in colorectal cancer cells and activating genes EGFL8 and opsin mw to treat ocular diseases such as rhodopsin deficiency. The filing date was March 5, 2025, with early publication on April 2, 2026.\n\nThis is a patent application publication, not a granted patent or regulatory rule. Inventors and applicants in the biotechnology and pharmaceutical sectors should review the published claims to assess potential competitive implications or freedom-to-operate concerns. No compliance actions are required by third parties; this publication informs the public of pending intellectual property rights.